Objectives: Investigation of the effect of macitentan on spermatogenesis, sperm quality and serum hormone concentrations of the hypothalamus-pituitary-adrenal and gonadal axes. PK, safety and tolerability.
Enrolled: 84 healthy subjects.
Evaluable testicular safety & other safety variables: All 84 subjects.
Evaluable PK: 65 subjects.
Demographics: Male; Caucasian (56), Black (25), other (3); Age: 18–44 years; Weight: 51.0–110.2 kg; BMI: 18.3–30.0 kg/m2.
Assessment report
EMA/CHMP/457699/2013 Page 33/105
Study
Characteristics
Treatments: Once daily oral macitentan 10 mg tablet or placebo for 12 weeks.
Design: Double-blind, placebo-controlled, parallel group.
Thorough QT study
AC-055-114
Objectives: Investigation of the effect of repeated daily doses of 10 mg and 30 mg macitentan on the QT/QTc interval in healthy male and female subjects.
Enrolled: 64 healthy subjects.
Evaluable PK: 62 subjects (Treatments A–D).
Evaluable safety (cardiodynamic): 64 subjects (Treatments A–B), 63 subjects (Treatments C–D).
Evaluable PK/cardiodynamic: 62 subjects (Treatments A–D).
Demographics: 26 male, 38 female; Caucasian, 63 subjects; Hispanic, 1 subject; Age: 23–55 years; Weight: 50.1–98.5 kg; BMI: 19.1–28.0 kg/m2.